Respiratory Tract Inflammatory Disorders is an indication for drug development with over 450 pipeline drugs currently active. According to GlobalData, preregistered drugs for Respiratory Tract Inflammatory Disorders have a 93.75% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Respiratory Tract Inflammatory Disorders compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Respiratory Tract Inflammatory Disorders overview

Respiratory tract inflammatory disorders, also known as lung diseases, include asthma, chronic obstructive pulmonary disease (COPD, pulmonary fibrosis, bronchiectasis, chronic bronchitis. Causes include pathogens, toxins, pollutants, irritants, and allergens, respiratory infections, lung diseases, air pollution, tobacco smoking, occupational risks. Inhaled corticosteroids and bronchodilators are used for treatment.

For a complete picture of PTSR and LoA scores for drugs in Respiratory Tract Inflammatory Disorders, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.